Diabetes, biochemical markers of bone turnover, diabetes control, and bone

Frontiers in Endocrinology

Volumn 4, Issue MAR, 2013, Pages

  Starup Linde, Jakob ^a,b  

^a AALBORG UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biochemical markers; Bone; Bone turnover; Diabetes mellitus; Glycemic control; Markers of bone turnover

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYPROLINE; LEPTIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; PYRIDINOLINE; SCLEROSTIN; SOMATOMEDIN C; UNINDEXED DRUG; WNT PROTEIN;

ADIPOSE TISSUE; BONE; BONE CELL; BONE TURNOVER; DIABETES CONTROL; DIABETES MELLITUS; DISEASE SEVERITY; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; REVIEW;

EID: 84884179747     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00021     Document Type: Review

References (91)

1. Abd El Dayem, S. M., El-Shehaby, A. M., Abd El Gafar, A., Fawzy, A., and Salama, H. (2011). Bone density, body composition, and markers of bone remodeling in type 1 diabetic patients. Scand. J. Clin. Lab. Invest. 71, 387-393.
2. Aboelasrar, M., Farid, S., El Maraghy, M., and Mohamedeen, A. (2010). Serum osteocalcin, zinc nutritive status and bone turnover in children and adolescents with type 1 diabetes mellitus. Pediatr. Diabetes 11, 50.
3. Achemlal, L., Tellal, S., Rkiouak, F., Nouijai, A., Bezza, A., Derouiche, E. M., et al. (2005). Bone metabolism in male patients with type 2 diabetes. Clin. Rheumatol. 24, 493-496.
4. Alikhani, M., Alikhani, Z., Boyd, C., MacLellan, C. M., Raptis, M., Liu, R., et al. (2007). Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40, 345-353.
5. American Diabetes Association. (2012). Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl. 1), S64-S71.
6. Andress, D. L., Hercz, G., Kopp, J. B., Endres, D. B., Norris, K. C., Coburn, J. W., et al. (1987). Bone histomorphometry of renal osteodystrophy in diabetic patients. J. Bone Miner. Res. 2, 525-531.
7. Armas, L. A., Akhter, M. P., Drincic, A., and Recker, R. R. (2012). Trabecular bone histomorphometry in humans with Type 1 Diabetes mellitus. Bone 50, 91-96.
8. Bao, Y. Q., Zhou, M., Zhou, J., Lu, W., Gao, Y. C., Pan, X. P., et al. (2011). Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 38, 50-54.
9. Bending, D., Zaccone, P., and Cooke, A. (2012). Inflammation and type one diabetes. Int. Immunol. 24, 339-346.
10. Berg, A. H., Combs, T. P., Du, X., Brownlee, M., and Scherer, P. E. (2001). The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947- 953.
11. Berner, H. S., Lyngstadaas, S. P., Spahr, A., Monjo, M., Thommesen, L., Drevon, C. A., et al. (2004). Adiponectin and its receptors are expressed in bone-forming cells. Bone 35, 842-849.
12. Brandao, F. R., Vicente, E. J., Daltro, C. H., Sacramento, M., Moreira, A., and Adan, L. (2007). Bone metabolism is linked to disease duration and metabolic control in type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 78, 334-339.
13. Calle, M. C., and Fernandez, M. L. (2012). Inflammation and type 2 diabetes. Diabetes Metab. 38, 183-191.
14. Calvo, M. S., Eyre, D. R., and Gundberg, C. M. (1996). Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17, 333-368.
15. Campos Pastor, M. M., Lopez-Ibarra, P. J., Escobar-Jimenez, F., Serrano Pardo, M. D., and Garcia-Cervigon, A. G. (2000). Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos. Int. 11, 455-459.
16. Capoglu, I., Ozkan, A., Ozkan, B., and Umudum, Z. (2008). Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. J. Int. Med. Res. 36, 1392-1398.
17. Christensen, J. O., and Svendsen, O. L. (1999). Bone mineral in pre and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos. Int. 10, 307-311.
18. Clowes, J. A., Allen, H. C., Prentis, D. M., Eastell, R., and Blumsohn, A. (2003). Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J. Clin. Endocrinol. Metab. 88, 4867-4873.
19. Combs, T. P., Berg, A. H., Obici, S., Scherer, P. E., and Rossetti, L. (2001). Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108, 1875-1881.
20. Confavreux, C. B., Levine, R. L., and Karsenty, G. (2009). A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol. Cell. Endocrinol. 310, 21-29.
21. Cutrim, D. M. S. L., Pereira, F. A., de Paula, F. J. A., and Foss, M. C. (2007). Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz. J. Med. Biol. Res. 40, 221-227.
22. Danielson, K. K., Elliott, M. E., Lecaire, T., Binkley, N., and Palta, M. (2009). Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos. Int. 20, 923-933.
23. Delmas, P. D. (1991). What do we know about biochemical bone markers?. Baillieres Clin. Obstet. Gynaecol. 5, 817-830.
24. Dobnig, H., Piswanger-Solkner, J. C., Roth, M., Obermayer-Pietsch, B., Tiran, A., Strele, A., et al. (2006). Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J. Clin. Endocrinol. Metab. 91, 3355-3363.
25. Ferron, M., Hinoi, E., Karsenty, G., and Ducy, P. (2008). Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. U.S.A. 105, 5266-5270.
26. Ferron, M., McKee, M. D., Levine, R. L., Ducy, P., and Karsenty, G. (2012). Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 50, 568-575.
27. Frystyk, J., Skjaerbaek, C., Vestbo, E., Fisker, S., and Orskov, H. (1999). Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab. Res. Rev. 15, 314-322.
28. Galluzzi, F., Stagi, S., Salti, R., Toni, S., Piscitelli, E., Simonini, G., et al. (2005). Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur. J. Endocrinol. 153, 879-885.
29. Garcia-Martin, A., Rozas-Moreno, P., Reyes-Garcia, R., Morales-Santana, S., Garcia-Fontana, B., Garcia-Salcedo, J. A., et al. (2012a). Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 234-241.
30. Garcia-Martin, A., Reyes-Garcia, R., Rozas-Moreno, P., Morales-Santana, S., Garcia-Fontana, B., and Munoz-Torres, M. (2012b). Role of serum sclerostin on bone metabolism in patients with type 2 diabetes mellitus. Osteoporos. Int. 23, S150-S151.
31. Garnero, P. (2009). Bone markers in osteoporosis. Curr. Osteoporos. Rep. 7, 84-90.
32. Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., et al. (2012). Circulating Sclerostin levels and bone turnover in type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1737-1744.
33. Gerdhem, P., Isaksson, A., Akesson, K., and Obrant, K. J. (2005). Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos. Int. 16, 1506-1512.
34. Gregorio, F., Cristallini, S., Santeusanio, F., Filipponi, P., and Fumelli, P. (1994). Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?. Diabetes Res. Clin. Pract. 23, 43-54.
35. Hamada, Y., Fujii, H., and Fukagawa, M. (2009). Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl. 1), S35-S38.
36. Hamed, E. A., Faddan, N. H., Elhafeez, H. A., and Sayed, D. (2011). Parathormone-25(OH)-vitamin D axis and bone status in children and adolescents with type 1 diabetes mellitus. Pediatr. Diabetes 12, 536-546.
37. Hamilton, E. J., Rakic, V., Davis, W. A., Chubb, S. A. P., Kamber, N., Prince, R. L., et al. (2012). A five-year prospective study of bone mineral density in men and women with diabetes: the Fremantle Diabetes Study. Acta Diabetol. 49, 153-158.
38. Hampson, G., Evans, C., Petitt, R. J., Evans, W. D., Woodhead, S. J., Peters, J. R., et al. (1998). Bone mineral density, collagen type 1 (alpha) 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 41, 1314-1320.
39. Herrero, S., Calvo, O. M., Garcia-Moreno, C., Martin, E., San Roman, J. I., Martin, M., et al. (1998). Low bone density with normal bone turnover in ovariectomized and streptozotocin-induced diabetic rats. Calcif. Tissue Int. 62, 260-265.
40. Holloway, W. R., Collier, F. M., Aitken, C. J., Myers, D. E., Hodge, J. M., Malakellis, M., et al. (2002). Leptin inhibits osteoclast generation. J. Bone Miner. Res. 17, 200-209.
41. Horowitz, M. C., Xi, Y., Wilson, K., and Kacena, M. A. (2001). Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev. 12, 9-18.
42. Hwang, Y. C., Jeong, I. K., Ahn, K. J., and Chung, H. Y. (2012). Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos. Int. 23, 1337-1342.
43. Inaba, M., Nishizawa, Y., Mita, K., Kumeda, Y., Emoto, M., Kawagishi, T., et al. (1999). Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos. Int. 9, 525-531.
44. Johansson, A. G., Lindh, E., Blum, W. F., Kollerup, G., Sorensen, O. H., and Ljunghall, S. (1996). Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 81, 44-48.
45. Kanazawa, I., Yamaguchi, T., and Sugimoto, T. (2010). Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1- year treatment of type 2 diabetes mellitus. Metab. Clin. Exp. 59, 1252-1256.
46. Kanazawa, I., Yamaguchi, T., and Sugimoto, T. (2011a). Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 92, 393-399.
47. Kanazawa, I., Yamaguchi, T., Yamauchi, M., Yamamoto, M., Kurioka, S., Yano, S., et al. (2011b). Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos. Int. 22, 187-194.
48. Kanazawa, I., Yamaguchi, T., Yamamoto, M., Yamauchi, M., Yano, S., and Sugimoto, T. (2009a). Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif. Tissue Int. 85, 228-234.
49. Kanazawa, I., Yamaguchi, T., Yamauchi, M., Yamamoto, M., Kurioka, S., Yano, S., et al. (2009b). Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 3031-3037.
50. Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M., Yamamoto, M., and Sugimoto, T. (2007). Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol. 8, 51. doi:10.1186/1471-2121-8-51
51. Lacativa, P. G., and Farias, M. L. (2010). Osteoporosis and inflammation. Arq. Bras. Endocrinol. Metabol. 54, 123-132.
52. Lappin, D. F., Eapen, B., Robertson, D., Young, J., and Hodge, P. J. (2009). Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. J. Clin. Periodontol. 36, 634-641.
53. Lee, N. K., Sowa, H., Hinoi:E., Ferron, M., Ahn, J. D., Confavreux, C., et al. (2007). Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469.
54. Leite Duarte, M. E., and da Silva, R. D. (1996). Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID). Rev. Hosp. Clin. Fac. Med. Sao Paulo 51, 7-11.
55. Leon, M., Larrodera, L., Lledo, G., and Hawkins, F. (1989). Study of bone loss in diabetes mellitus type 1. Diabetes Res. Clin. Pract. 6, 237-242.
56. Levy, L., Stern, Z., and Gutman, A. (1986). Plasma calcium and phosphate levels in an adult noninsulin-dependent diabetic population. Calcif. Tissue Int. 39, 316- 318.
57. Luo, X. H., Guo, L. J., Xie, H., Yuan, L. Q., Wu, X. P., Zhou, H. D., et al. (2006). Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J. Bone Miner. Res. 21, 1648-1656.
58. Luo, X. H., Guo, L. J., Yuan, L. Q., Xie, H., Zhou, H. D., Wu, X. P., et al. (2005). Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp. Cell Res. 309, 99-109.
59. Manolagas, S. C., and Almeida, M. (2007). Gone with the Wnts, beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 21, 2605-2614.
60. Mastrandrea, L. D., Wactawski-Wende, J., Donahue, R. P., Hovey, K. M., Clark, A., and Quattrin, T. (2008). Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 31, 1729-1735.
61. McNair, P., Madsbad, S., Christensen, M. S., Christiansen, C., Faber, O. K., Binder, C., et al. (1979). Bone mineral loss in insulin-treated diabetes mellitus, studies on pathogenesis. Acta Endocrinol. 90, 463-472.
62. Miazgowski, T., and Czekalski, S. (1998). A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulindependent diabetes mellitus. Osteoporos. Int. 8, 399-403.
63. Miazgowski, T., Noworyta-Zietara, M., Safranow, K., Ziemak, J., and Widecka, K. (2012). Serum adiponectin, bone mineral density and bone turnover markers in post-menopausal women with newly diagnosed Type2 diabetes, a 12-month follow-up. Diabet. Med. 29, 62-69.
64. Motyl, K. J., McCabe, L. R., and Schwartz, A. V. (2010). Bone and glucose metabolism, a two-way street. Arch. Biochem. Biophys. 503, 2-10.
65. Munoz-Torres, M., Jodar, E., Escobar-Jimenez, F., Lopez-Ibarra, P. J., and Luna, J. D. (1996). Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif. Tissue Int. 58, 316-319.
66. Neumann, T., Samann, A., Lodes, S., Kastner, B., Franke, S., Kiehntopf, M., et al. (2011). Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet. Med. 28, 872-875.
67. Ng, K. W. (2011). Regulation of glucose metabolism and the skeleton. Clin. Endocrinol. (Oxf) 75, 147-155.
68. Okuno, S., Ishimura, E., Tsuboniwa, N., Norimine, K., Yamakawa, K., Yamakawa, T., et al. (2013). Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos. Int. 24, 605-612.
69. Oz, S. G., Guven, G. S., Kilicarslan, A., Calik, N., Beyazit, Y., and Sozen, T. (2006). Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J. Natl. Med. Assoc. 98, 1598-1604.
70. Pedrazzoni, M., Ciotti, G., Pioli, G., Girasole, G., Davoli, L., Palummeri, E., et al. (1989). Osteocalcin levels in diabetic subjects. Calcif. Tissue Int. 45, 331-336.
71. Pondel, M. (2000). Calcitonin and calcitonin receptors, bone and beyond. Int. J. Exp. Pathol. 81, 405-422.
72. Puri, T., Blake, G. M., Curran, K. M., Carr, H., Moore, A. E., Colgan, N., et al. (2012). Semiautomatic region-of-interest validation at the femur in (18)F-fluoride PET/CT. J. Nucl. Med. Technol. 40, 168-174.
73. Raskin, P., Stevenson, M. R., Barilla, D. E., and Pak, C. Y. (1978). The hypercalciuria of diabetes mellitus, its amelioration with insulin. Clin. Endocrinol. (Oxf) 9, 329 -335.
74. Rasul, S., Ilhan, A., Reiter, M. H., Todoric, J., Farhan, S., Esterbauer, H., et al. (2012a). Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin. Endocrinol. (Oxf) 76, 499-505.
75. Rasul, S., Ilhan, A., Wagner, L., Luger, A., and Kautzky-Willer, A. (2012b). Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes, greater effects in male patients. Gend. Med. 9, 187-196.
76. Reid, I. R. (2002). Relationships among body mass, its components, and bone. Bone 31, 547-555.
77. Reid, I. R., Evans, M. C., Cooper, G. J., Ames, R. W., and Stapleton, J. (1993). Circulating insulin levels are related to bone density in normal postmenopausal women. Am. J. Physiol. 265, E655-E659.
78. Reyes-Garcia, R., Rozas-Moreno, P., Lopez-Gallardo, G., Garcia-Martin, A., Varsavsky, M., Aviles-Perez, M. D., et al. (2013). Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol. 50, 47-52.
79. Rosato, M. T., Schneider, S. H., and Shapses, S. A. (1998). Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif. Tissue Int. 63, 107-111.
80. Shu, A., Yin, M. T., Stein, E., Cremers, S., Dworakowski, E., Ives, R., et al. (2012). Bone structure and turnover in type 2 diabetes mellitus. Osteoporos. Int. 23, 635- 641.
81. Suzuki, K., Ishida, H., Takeshita, N., Taguchi, Y., Sugimoto, C., Nosaka, K., et al. (1998). Circulating levels of tartrate-resistant acid phosphatase in rat models of noninsulin- dependent diabetes mellitus. J. Diabetes Complicat. 12, 176-180.
82. Tamura, T., Yoneda, M., Yamane, K., Nakanishi, S., Nakashima, R., Okubo, M., et al. (2007). Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metab. Clin. Exp. 56, 623-628.
83. Valerio, G., del Puente, A., Esposito-del Puente, A., Buono, P., Mozzillo, E., and Franzese, A. (2002). The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm. Res. 58, 266-272.
84. Verhaeghe, J., Suiker, A. M., Visser, W. J., Van Herck, E., Van Bree, R., and Bouillon, R. (1992). The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J. Endocrinol. 134, 485-492.
85. Vestergaard, P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos. Int. 18, 427 -444.
86. Vestergaard, P., Rejnmark, L., and Mosekilde, L. (2009). Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif. Tissue Int. 84, 45-55.
87. WHO. (2012). Country and Regional Data. Available at, http, //www.who.int/diabetes/facts/world_figures/en/print.html 09/17
88. Wikipedia. (2012). Diabetes Mellitus. Available at, http, //en.wikipedia.org/wiki/Diabetes_mellitus 09/17
89. Wittrant, Y., Gorin, Y., Woodruff, K., Horn, D., Abboud, H. E., Mohan, S., et al. (2008). High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42, 1122-1130.
90. Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., et al. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110, 771-781.
91. Zhou, Y., Li, Y., Zhang, D., Wang, J., and Yang, H. (2010). Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res. Clin. Pract. 90, 261-269.